Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKD. - Wikidata - wikimedia - TriplyDB

Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKD.

Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKD.

http://www.wikidata.org/entity/Q41823201

about

Potent and selective chemical probe of hypoxic signalling downstream of HIF-α hydroxylation via VHL inhibition Recent advances in CKD and ESRD: A literature update.HIF-prolyl hydroxylases as therapeutic targets in erythropoiesis and iron metabolism Structural basis for oxygen degradation domain selectivity of the HIF prolyl hydroxylases.Renal Hypoxia in CKD; Pathophysiology and Detecting Methods.Induction of erythropoiesis by hypoxia-inducible factor prolyl hydroxylase inhibitors without promotion of tumor initiation, progression, or metastasis in a VEGF-sensitive model of spontaneous breast cancer.Current and future chemical therapies for treating anaemia in chronic kidney disease.Emerging drugs for the treatment of kidney disease-induced anemia.Hypoxia in Atherogenesis.Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients.Therapeutic targeting of the HIF oxygen-sensing pathway: Lessons learned from clinical studies.Hypoxia inducible factor (HIF) as a model for studying inhibition of protein-protein interactions.What are the Considerations in Balancing Benefits and Risks in Iron Treatment?: How Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitors May Change Iron Management in End-Stage Renal Disease.Intestinal hypoxia and hypoxia-induced signalling as therapeutic targets for IBD.Mechanisms and mediators of hypertension induced by erythropoietin and related molecules.Group-Based Optimization of Potent and Cell-Active Inhibitors of the von Hippel-Lindau (VHL) E3 Ubiquitin Ligase: Structure-Activity Relationships Leading to the Chemical Probe (2S,4R)-1-((S)-2-(1-Cyanocyclopropanecarboxamido)-3,3-dimethylbutanoyl)-Targeting Hypoxia Signaling for Perioperative Organ Injury.Induction of erythropoietin gene expression in epithelial cells by chemicals identified in GATA inhibitor screenings.Regulation of immunity and inflammation by hypoxia in immunological niches.Cell death-based approaches in treatment of the urinary tract-associated diseases: a fight for survival in the killing fields.By inhibiting PFKFB3, aspirin overcomes sorafenib resistance in hepatocellular carcinoma.Hypoxia-Inducible Factor and Its Role in the Management of Anemia in Chronic Kidney Disease.lmplementation of the prolyl hydroxylase inhibitor Roxadustat (FG-4592) and its main metabolites into routine doping controls.Hypoxia Induced Factor in Chronic Kidney Disease: Friend or Foe?Roxadustat in the treatment of anaemia in chronic kidney disease.A sensitive assay for ZYAN1 in human whole blood and urine utilizing positive LC-MS/MS electrospray ionization.Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China.Therapeutic Potential of a Prolyl Hydroxylase Inhibitor FG-4592 for Parkinson's Diseases in Vitro and in Vivo: Regulation of Redox Biology and Mitochondrial Function.Measurement properties of the Short Form-36 (SF-36) and the Functional Assessment of Cancer Therapy - Anemia (FACT-An) in patients with anemia associated with chronic kidney disease.An Exploratory Study of Daprodustat in Erythropoietin-Hyporesponsive Subjects.

P2860

Q28822022-3C3C3071-CCFB-41FC-A715-E5EEB5C96176 Q30275339-25FA63F9-4C3D-4FFF-910D-D4C9EC413E0C Q33926530-75C93F9C-6045-489C-9A5C-013957AAE11D Q34538526-4618D414-EB56-4A47-AE2B-9DCC344FC84F Q37653803-F9E531AF-C02E-4ED2-A3DF-A6E1394B305B Q37705646-A76A1DEA-0C9E-4D47-AE11-F0E9679BFD84 Q38690858-B3943F3B-CBBB-444B-9546-B16FD8734F15 Q38930912-30448F20-2959-4137-A489-4C426FC8834E Q38939115-A41B4EB1-E708-4F29-8B50-AFAE658DD95E Q39101277-5408B871-D643-4CE4-98CF-54550B13DD10 Q39291945-F5DE5AF3-8A69-462A-9607-BB057E51504B Q41559175-A53E519A-36BB-404D-A9F9-AC7D5A530116 Q46224147-DA439373-E0F0-4182-A47C-2A0A2B400CDB Q46260887-82928001-D5E3-4DBA-AF49-5A4062F50BFD Q47307152-54C00F10-7BAB-4185-B64F-6EDA85FB3BEE Q47324161-CC673783-DA18-45FC-9569-A0EFB5213567 Q47571628-4555B38A-2A1A-4DF3-A4DA-4152BD4B982B Q47634204-B7B6277E-A8A0-4107-8E26-EB6982BA5898 Q47708732-C3C86391-DB3C-4DF4-B9BC-075C325CC0FC Q47711163-5394E85D-638B-4CFC-BD9E-9F90C6F64D34 Q47878727-5AE954EE-D917-4209-92C1-3A96FE042B1D Q48140646-F1E19647-E3A1-4C15-B9CE-B4037CC2406E Q48319000-50CB3742-8B3D-450B-BB40-CBBAD5182840 Q48512043-A241713E-6918-416B-82B4-214C06039839 Q49649941-FB218918-5C7C-4232-8735-57D078E05B35 Q50659180-D18F8B11-68C1-462F-B841-21DB17B05A3A Q53383073-EDF9B41D-E2C8-4832-A51A-384C90BFF3CD Q54979172-412A24F1-BD65-434D-B239-3B2E1229C994 Q55379461-2994714C-3C73-441C-B291-7E1C4C3CAB3B Q55509823-869C4386-B794-42F3-A06B-9BBE75773E7E

P2860

Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKD.

http://www.wikidata.org/entity/Q41823201

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Oral Hypoxia-Inducible Factor ...... f Anemia in Patients with CKD.

@en

type

label

Oral Hypoxia-Inducible Factor ...... f Anemia in Patients with CKD.

@en

prefLabel

Oral Hypoxia-Inducible Factor ...... f Anemia in Patients with CKD.

@en

P1433

Q41823201-8B146819-16CF-4CDA-88FB-49AB6E5BEF94

P1476

Q41823201-CB765832-2552-4453-88D2-73C184794598

P2093

Q41823201-0C8EA069-A145-4FC8-BBCA-2161A78A743C

Q41823201-3E99445B-42D6-4D4A-8177-6D13F65ADCD0

Q41823201-49E84CB5-11DE-4E7A-92FE-991543EC46A4

Q41823201-5E31869B-9BB8-4640-B9A5-769ECCE0CA86

Q41823201-77FBCBA1-7BFF-41D6-B1F9-26D3ABA36D74

Q41823201-834F1DA5-193F-4179-8AAA-97A4766724B8

Q41823201-8A95080C-6185-40A4-95FC-42FF67225F80

Q41823201-986235DE-EA2E-415C-A561-C24337697A36

Q41823201-9F1F5879-4031-4157-BAD3-8E61715721A7

Q41823201-AB479714-011F-4F77-98C8-2C939977CC46

P2860

Q41823201-071D7290-FEE8-4262-91CE-C008AC43C451

Q41823201-0835CA62-86CE-4402-A3F0-B72654F9D7E6

Q41823201-122674EF-4A6C-4202-B78D-8B283C456BB1

Q41823201-14324FDB-0441-4623-BA55-4735FBAF2019

Q41823201-1C130B56-A273-44E6-B25F-37808CAECBE8

Q41823201-255135F0-948B-4C55-8AD6-1FDEC1556359

Q41823201-29F644D8-4AFC-4B0F-86B1-8AAE74699A87

Q41823201-369B1DFE-9138-4583-9ABD-BE0F1151CCFE

Q41823201-43439512-AB5C-4F49-8570-4C7317574342

Q41823201-5269474B-899E-460D-92DD-413C4254A10D

P304

Q41823201-A2722444-8F98-4F83-8EC2-D01EF07AF979

P31

Q41823201-55318367-D9D7-4E06-9FF5-D9A9D568254F

P356

Q41823201-E1E87060-0BCA-4350-A720-76CE2B9F35C2

P433

Q41823201-A34B6AFB-839A-4038-BB4F-DF66955D337C

P478

Q41823201-4CB575E2-0F4A-4725-BAE7-0C0F7F29B3F7

P577

Q41823201-86D13512-38FB-451C-81A7-D7BF9CF53C7D

P5875

Q41823201-220EB029-7F9C-428E-8483-C9C6F79FD958

P698

Q41823201-C5F4C172-3ACD-4D88-9CC5-D93C5CBD8AE6

P921

Q41823201-8832806C-6D36-4E87-B65E-ACB2E64804F1

Q41823201-EEA26D5A-A7AE-4A33-A235-A25E4DE26E53

P932

Q41823201-311E715F-45E2-45B9-946C-81FAE49A5ABD

P356

P1433

Clinical Journal of the American Society of Nephrology

P1476

Oral Hypoxia-Inducible Factor ...... f Anemia in Patients with CKD.

@en

P2093

Anatole Besarab

http://www.w3.org/2001/XMLSchema#string

Brian K Roberts

http://www.w3.org/2001/XMLSchema#string

Chao H Sun

http://www.w3.org/2001/XMLSchema#string

James E Novak

http://www.w3.org/2001/XMLSchema#string

John H Durham

http://www.w3.org/2001/XMLSchema#string

Jose L Cangiano

http://www.w3.org/2001/XMLSchema#string

Joseph R Aiello

http://www.w3.org/2001/XMLSchema#string

Khalil G Saikali

http://www.w3.org/2001/XMLSchema#string

Kin-Hung Peony Yu

http://www.w3.org/2001/XMLSchema#string

Lynda A Szczech

http://www.w3.org/2001/XMLSchema#string

P2860

Normalization of hemoglobin level in patients with chronic kidney disease and anemia

A randomized controlled study of iron supplementation in patients treated with erythropoietin

Prevalence of chronic kidney disease in the United States

The associations between race and geographic area and quality-of-care indicators in patients approaching ESRD.

Timing of erythropoiesis-stimulating agent initiation and adverse outcomes in nondialysis CKD: a propensity-matched observational study.

Association between high-dose erythropoiesis-stimulating agents, inflammatory biomarkers, and soluble erythropoietin receptors.

Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial.

A rationale for an individualized haemoglobin target.

Intestinal hypoxia-inducible factor-2alpha (HIF-2alpha) is critical for efficient erythropoiesis

Anaemia management prior to dialysis: cardiovascular and cost-benefit observations.

P304

982-991

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2215/CJN.06890615

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P577

2016-04-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

301541417

http://www.w3.org/2001/XMLSchema#string

P698

27094610

http://www.w3.org/2001/XMLSchema#string

P921

P932

4891748

http://www.w3.org/2001/XMLSchema#string